Shuttle Pharma Provides Corporate Update and Reports 2024 Results
Shuttle Pharmaceuticals (NASDAQ: SHPH) has provided a corporate update for 2024, highlighting significant progress in its cancer treatment programs. The company reported 40% enrollment completion in the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with 16 out of 40 initial patients enrolled and 8 patients completing all seven cycles.
The trial is being conducted at several prestigious cancer centers including Georgetown University Medical Center and UNC Medical Center. Additionally, Shuttle Pharma's Diagnostics subsidiary entered a research agreement with UCSF to develop a PSMA ligand for cancer diagnosis and therapy.
The company secured additional funding, including a $237,500 investment from CEO Dr. Anatoly Dritschilo. The company's focus remains on developing radiation sensitizers to enhance cancer treatment outcomes and advancing diagnostic tools for predicting radiation therapy success, particularly in prostate cancer treatment.
- 40% completion of Phase 2 trial enrollment for glioblastoma treatment
- Partnership with six major cancer centers for clinical trials
- New research agreement with UCSF for diagnostic development
- CEO demonstrates confidence through $237,500 personal investment
- Remaining 60% of initial trial enrollment still pending
- No reported revenue or financial metrics
- Early-stage company with no commercialized products
Insights
Shuttle Pharmaceuticals reports 40% enrollment completion (16 of 40 patients) in its Phase 2 trial of Ropidoxuridine for glioblastoma, with half of enrolled patients having completed all treatment cycles. This enrollment rate appears moderately encouraging for a small-cap biotech, though the timeline to complete the remaining 60% will be critical to watch as glioblastoma trials often face recruitment challenges.
The company's dual focus on radiation sensitizers and diagnostics represents an interesting strategic approach, particularly the PSMA theranostic program which aligns with growing interest in targeted radiopharmaceuticals. However, this two-pronged strategy raises questions about resource allocation for a company with just $2.5 million market cap.
Management's personal investment of
The glioblastoma space remains challenging with numerous failed trials historically, though radiation sensitizers represent a mechanistically sound approach. Ropidoxuridine's differentiation from competitors and potential efficacy signals from the first cohort of patients will be important determinants of value.
For investors, key upcoming catalysts include interim data from the Phase 2 trial, potential partnership announcements to extend runway, and progress in the diagnostic subsidiary that could diversify risk. The extremely low market capitalization suggests significant investor skepticism that will require compelling clinical data to overcome.
Shuttle Pharmaceuticals' update reveals a company making incremental clinical progress while navigating severe financial constraints. With a market cap of just
The CEO's
The 40% enrollment rate in their glioblastoma trial demonstrates operational execution, but the absence of any financial metrics in this update is concerning. The company appears to be prioritizing clinical milestones over financial transparency, a strategy that typically precedes additional capital raises.
While their dual approach to therapeutics and diagnostics creates multiple potential value streams, it also divides resources. The PSMA theranostic program enters a competitive landscape dominated by well-capitalized players including Novartis and Point Biopharma.
For investors, the risk-reward profile is heavily skewed: the company must either secure substantial partnership funding, demonstrate compelling Phase 2 data to enable favorable financing, or face significant dilution. The extremely low valuation suggests the market has assigned minimal probability to clinical success, creating potential asymmetric returns if the Ropidoxuridine data surprises positively.
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
Shuttle Pharma’s recent highlights include the following:
- Accelerated patient enrollment of the Company’s key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma with
40% enrollment in the initial randomized portion. As of today, a total of 16 of the initial 40 patients have been enrolled, with 8 of the 16 patients having completed all seven cycles. - The Phase 2 trial is being conducted at nationally recognized cancer centers, including Georgetown University Medical Center, Allegheny Health Network (AHN) Cancer Institute, UNC Medical Center, the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, and Miami Cancer Institute, part of Baptist Health South Florida.
- Continued advancement of the Company’s Diagnostics subsidiary through the entry of a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of a ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.
- Launched new corporate website highlighting Shuttle Pharma’s dual approach to Cancer Therapeutics and Diagnostics. Visit https://shuttlepharma.com/ to learn more about how Shuttle Pharma is developing novel therapies designed to increase cancer cure rates, prolong patient survival, and improve quality of life.
- Management has made significant investments into the business, including the Company’s Chief Executive Officer, Dr. Anatoly Dritschilo, providing
$237,500 along with other investors in a recent financing transaction.
“This past year has been highlighted by numerous scientific developments, led by the commencement of our Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma,” stated Shuttle Pharma’s Chairman and CEO, Anatoly Dritschilo, M.D. “We are more than one-third complete with the initial randomized portion of enrollment with a target to complete enrollment in the coming year. This clinical trial is critical to the broader radiation therapy industry as we look to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma.”
“We have also made significant progress to advance our diagnostic subsidiary, Shuttle Diagnostics, where our approach is to offer prognosis and guide treatment decisions, with the goal of providing clinicians and patients with a means of measuring the potential for success of radiation therapy for their cancer treatment. Through the development of a PC-Rad test for predicting outcomes following radiation therapy for localized prostate cancer, and a PSMA-B ligand, a theranostic molecule offering diagnosis and therapeutics for metastatic prostate cancer, we offer a completely new way to predict success for a specific treatment.”
“2025 is set to be a year of scientific milestones. I look forward to the continued progress made as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world,” Dr. Dritschilo concluded.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
What is the current enrollment status of SHPH's Phase 2 Ropidoxuridine trial for glioblastoma?
Which major cancer centers are participating in SHPH's Phase 2 glioblastoma trial?
What is the focus of SHPH's new research agreement with UCSF?
How much did SHPH CEO Dr. Anatoly Dritschilo invest in the recent financing?
